Citizens Jmp Forecasts Strong Price Appreciation for AtriCure (NASDAQ:ATRC) Stock

AtriCure (NASDAQ:ATRC) had its target price lifted by analysts at Citizens Jmp from $52.00 to $68.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage presently has a “market outperform” rating on the medical device company’s stock. Citizens Jmp’s price objective would suggest a potential upside of 17.91% from the company’s previous close.

Other equities research analysts have also issued reports about the company. Freedom Capital lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. Weiss Ratings upgraded AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Citigroup restated a “market outperform” rating on shares of AtriCure in a research note on Wednesday. BTIG Research boosted their target price on shares of AtriCure from $55.00 to $63.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Finally, Raymond James Financial set a $52.00 target price on shares of AtriCure in a report on Tuesday, July 21st. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AtriCure has an average rating of “Hold” and a consensus price target of $55.70.

AtriCure Stock Up 3.9%

NASDAQ ATRC opened at $57.67 on Wednesday. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. AtriCure has a 52 week low of $25.36 and a 52 week high of $61.70. The stock’s 50-day moving average price is $53.28 and its 200-day moving average price is $38.68. The company has a market capitalization of $2.93 billion, a P/E ratio of 274.63 and a beta of 1.24.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same quarter in the prior year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts predict that AtriCure will post 0.29 earnings per share for the current year.

Insider Activity

In other AtriCure news, insider Salvatore Privitera sold 4,519 shares of AtriCure stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $60.00, for a total transaction of $271,140.00. Following the transaction, the insider directly owned 142,745 shares of the company’s stock, valued at $8,564,700. The trade was a 3.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Karl Dahlquist sold 9,370 shares of AtriCure stock in a transaction on Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the sale, the insider owned 87,319 shares in the company, valued at $4,269,025.91. This represents a 9.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 74,868 shares of company stock valued at $3,317,897 in the last quarter. Insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On AtriCure

Institutional investors and hedge funds have recently made changes to their positions in the stock. Harbor Investment Advisory LLC acquired a new position in shares of AtriCure during the second quarter worth $40,000. Allworth Financial LP acquired a new position in AtriCure in the 2nd quarter valued at about $43,000. Integrated Wealth Concepts LLC purchased a new position in AtriCure during the 2nd quarter worth $46,000. Fifth Third Bancorp purchased a new position in shares of AtriCure during the 1st quarter worth approximately $51,000. Finally, Global Retirement Partners LLC acquired a new stake in shares of AtriCure in the second quarter valued at about $52,000. 99.11% of the stock is owned by institutional investors and hedge funds.

AtriCure Company Profile

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.